Geneva, June 4 -- International Clinical Trials Registry received information related to the study (NCT06985498) titled 'CD22/CD19 CAR-T and Blinatumomab Combined With Auto-HSCT Sandwich Strategy as Consolidation Therapy for B-ALL' on May 15.
Study Type: Interventional
Study Design:
Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).
Primary Sponsor: The First Affiliated Hospital of Soochow University
Condition:
Acute Lymphobkastic Leukemia
Intervention:
Combination Product: Sandwich stratergy
Recruitment Status: Not recruiting
Phase: Phase 2
Date of First Enrollment: June 1, 2025
Target Sample Size: 40
To know more, visit https://clinicaltrials.gov/ct2/sho...